Chemical giant LyondellBasell has successfully negotiated greater financial flexibility, though the amended terms of its credit agreement come with specific limitations on capital returns to shareholders. The development coincides with a downward revision of the stock’s price target by investment bank Rothschild, which nonetheless maintains its positive outlook on the equity.
Credit Agreement Amendments Offer Strategic Leverage
Effective September 10, a key amendment to LyondellBasell’s credit facility permits the company to operate with a higher leverage ratio through 2027. This adjustment to the covenant, known as the Maximum Leverage Ratio, provides the multinational with crucial operational breathing room amidst a challenging market environment.
In exchange for this increased financial latitude, the company has agreed to restrict share buybacks and dividend increases. The only repurchases exempt from these limitations are those intended to offset dilution. These conditions also extend to the firm’s $900 million receivables facility.
Market Analysts Recalibrate Short-Term Expectations
Reflecting a reassessment of near-term earnings potential, Rothschild & Co. reduced its price target on LyondellBasell shares from $80 to $75 just two days after the credit amendment was announced. Despite this adjustment, the bank reaffirmed its “buy” recommendation for the stock.
Should investors sell immediately? Or is it worth buying Strategy?
This revised assessment follows the company’s disappointing quarterly results released on August 1. Adjusted earnings per share plummeted 71.8% to $0.62, significantly missing analyst forecasts. Revenue also declined, contracting 11.8% to $7.7 billion.
Broader Strategic Initiatives Underway
The credit agreement revision forms part of a larger strategic overhaul currently in progress. Management is actively reshaping its portfolio, with plans to divest four of its European manufacturing facilities. Concurrently, the company is implementing a comprehensive program designed to enhance liquidity, which is projected to generate at least $1.1 billion in cash flow improvements during 2025 and 2026.
Despite present headwinds, the consensus among market experts remains cautiously neutral. The average rating from 19 analysts stands at “hold,” while the median price target suggests potential appreciation from current levels—contingent on stabilization in global markets and the successful execution of management’s strategic plans.
Ad
Strategy Stock: Buy or Sell?! New Strategy Analysis from December 19 delivers the answer:
The latest Strategy figures speak for themselves: Urgent action needed for Strategy investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 19.
Strategy: Buy or sell? Read more here...
